168 related articles for article (PubMed ID: 14577649)
1. Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their design.
Tomita N; Ogihara T; Morishita R
Curr Drug Targets; 2003 Nov; 4(8):603-8. PubMed ID: 14577649
[TBL] [Abstract][Full Text] [Related]
2. Application of decoy oligodeoxynucleotides-based approach to renal diseases.
Tomita N; Azuma H; Kaneda Y; Ogihara T; Morishita R
Curr Drug Targets; 2004 Nov; 5(8):717-33. PubMed ID: 15578952
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of decoy oligonucleotides strategy in cardiovascular diseases.
Tomita N; Ogihara T; Morishita R
Expert Rev Cardiovasc Ther; 2003 Sep; 1(3):463-70. PubMed ID: 15030273
[TBL] [Abstract][Full Text] [Related]
4. [Oligonucleotide-based therapy as a potential new pharmacotherapy].
Morishita R
Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):123-30. PubMed ID: 10876797
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy with transcription factor decoy oligonucleotides as a potential treatment for cardiovascular diseases.
Tomita N; Azuma H; Kaneda Y; Ogihara T; Morishita R
Curr Drug Targets; 2003 May; 4(4):339-46. PubMed ID: 12699354
[TBL] [Abstract][Full Text] [Related]
6. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease.
Morishita R; Higaki J; Tomita N; Ogihara T
Circ Res; 1998 Jun; 82(10):1023-8. PubMed ID: 9622154
[TBL] [Abstract][Full Text] [Related]
7. Potential therapeutic applications of decoy oligonucleotides.
Tomita N; Morishita R; Tomita T; Ogihara T
Curr Opin Mol Ther; 2002 Apr; 4(2):166-70. PubMed ID: 12044038
[TBL] [Abstract][Full Text] [Related]
8. Oligonucleotide-based gene therapy for cardiovascular disease: are oligonucleotide therapeutics novel cardiovascular drugs?
Morishita R; Aoki M; Kaneda Y
Curr Drug Targets; 2000 Jul; 1(1):15-23. PubMed ID: 11475534
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic potential of oligonucleotide-based therapy in cardiovascular disease.
Morishita R; Kaneda Y; Ogihara T
BioDrugs; 2003; 17(6):383-9. PubMed ID: 14614761
[TBL] [Abstract][Full Text] [Related]
10. An oligonucleotide decoy for transcription factor E2F inhibits mesangial cell proliferation in vitro.
Tomita N; Horiuchi M; Tomita S; Gibbons GH; Kim JY; Baran D; Dzau VJ
Am J Physiol; 1998 Aug; 275(2):F278-84. PubMed ID: 9691019
[TBL] [Abstract][Full Text] [Related]
11. [Application of decoy strategy].
Morishita R; Ogihara T
Nihon Rinsho; 1996 Sep; 54(9):2583-90. PubMed ID: 8890596
[TBL] [Abstract][Full Text] [Related]
12. Molecular strategy using cis-element 'decoy' of E2F binding site inhibits neointimal formation in porcine balloon-injured coronary artery model.
Nakamura T; Morishita R; Asai T; Tsuboniwa N; Aoki M; Sakonjo H; Yamasaki K; Hashiya N; Kaneda Y; Ogihara T
Gene Ther; 2002 Apr; 9(8):488-94. PubMed ID: 11948373
[TBL] [Abstract][Full Text] [Related]
13. Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease.
Tomita N; Kashihara N; Morishita R
Clin Exp Nephrol; 2007 Mar; 11(1):7-17. PubMed ID: 17384993
[TBL] [Abstract][Full Text] [Related]
14. Role of transcriptional cis-elements, angiotensinogen gene-activating elements, of angiotensinogen gene in blood pressure regulation.
Morishita R; Higaki J; Tomita N; Aoki M; Moriguchi A; Tamura K; Murakami K; Kaneda Y; Ogihara T
Hypertension; 1996 Mar; 27(3 Pt 2):502-7. PubMed ID: 8613193
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model.
Kawamura I; Morishita R; Tomita N; Lacey E; Aketa M; Tsujimoto S; Manda T; Tomoi M; Kida I; Higaki J; Kaneda Y; Shimomura K; Ogihara T
Gene Ther; 1999 Jan; 6(1):91-7. PubMed ID: 10341880
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for attenuating cardiac allograft arteriopathy using ex vivo E2F decoy transfection by HVJ-AVE-liposome method in mice and nonhuman primates.
Kawauchi M; Suzuki J; Morishita R; Wada Y; Izawa A; Tomita N; Amano J; Kaneda Y; Ogihara T; Takamoto S; Isobe M
Circ Res; 2000 Nov; 87(11):1063-8. PubMed ID: 11090553
[TBL] [Abstract][Full Text] [Related]
17. Development of novel decoy oligonucleotides: advantages of circular dumb-bell decoy.
Tomita N; Tomita T; Yuyama K; Tougan T; Tajima T; Ogihara T; Morishita R
Curr Opin Mol Ther; 2003 Apr; 5(2):107-12. PubMed ID: 12772498
[TBL] [Abstract][Full Text] [Related]
18. Novel E2F decoy oligodeoxynucleotides inhibit in vitro vascular smooth muscle cell proliferation and in vivo neointimal hyperplasia.
Ahn JD; Morishita R; Kaneda Y; Kim HS; Chang YC; Lee KU; Park JY; Lee HW; Kim YH; Lee IK
Gene Ther; 2002 Dec; 9(24):1682-92. PubMed ID: 12457282
[TBL] [Abstract][Full Text] [Related]
19. Molecular therapy to inhibit NFkappaB activation by transcription factor decoy oligonucleotides.
Morishita R; Tomita N; Kaneda Y; Ogihara T
Curr Opin Pharmacol; 2004 Apr; 4(2):139-46. PubMed ID: 15063357
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of NFkappaB activation using cis-element 'decoy' of NFkappaB binding site reduces neointimal formation in porcine balloon-injured coronary artery model.
Yamasaki K; Asai T; Shimizu M; Aoki M; Hashiya N; Sakonjo H; Makino H; Kaneda Y; Ogihara T; Morishita R
Gene Ther; 2003 Feb; 10(4):356-64. PubMed ID: 12595894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
